August 26, 2013

Sanofi Pasteur’s Fluzone High-Dose Vaccine Significantly More Effective Than Standard Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older

Efficacy trial in more than 30,000 older adults meets primary endpoint for superior efficacy

 

Sanofi Pasteur’s Fluzone High-Dose Vaccine Significantly More Effective Than Standard Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older
Efficacy trial in more than 30,000 older adults meets primary endpoint for superior efficacy

Lyon, France – August 26, 2013 – Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), today announced topline results of a large-scale, multi-center efficacy trial in people 65 years of age and older showing a superior clinical benefit of Fluzone® High-Dose (Influenza Virus Vaccine) relative to the standard dose of Fluzone vaccine in preventing influenza.